Lei Zhao

Ms. Lei Zhao

Stanford University, Palo Alto, California, USA
orcid

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 August 2022 in Biomedicines
Verified
Journal Article
Open access
PDF file
LZLei Zhao
Lei Zhao
LLLawrence L. Leung
Lawrence L. Leung
JMJohn Morser
John Morser
Chemerin is the product of the RARRES2 gene which is secreted as a precursor of 143 amino acids. That precursor is inactive, but proteases from the coagulation and fibrinolytic cascades, as well as from inflammatory reactions, process the C-terminus of chemerin to first activate it and then subsequently inactivate it. Chemerin can signal via two G protein-coupled receptors, chem1 and chem2, as well as be bound to a third non-signaling receptor, CCRL2. Chemerin is produced by the liver and secreted into the circulation as a precursor, but it is also expressed in some tissues where it can be activated locally. This review discusses the specific tissue expression of the components of the chemerin system, and the role of different proteases in regulating the activation and inactivation of chemerin. Methods of identifying and determining the levels of different chemerin forms in both mass and activity assays are reviewed. The levels of chemerin in circulation are correlated with certain disease conditions, such as patients with obesity or diabetes, leading to the possibility of using chemerin as a biomarker.

16 June 2020 in Biotechnology and Bioengineering
Verified
Journal Article
Closed access
PDF file
ZLZhanglin Lin
Zhanglin Lin
QLQiao Lin
Qiao Lin
JLJiahui Li
Jiahui Li
MPMarco Pistolozzi
Marco Pistolozzi
LZLei Zhao
Lei Zhao
Yanrui YeYanrui Ye
Yanrui Ye

4 July 2018 in Arthritis Research & Therapy
Verified
Journal Article
Open access
PDF file
LZLei Zhao
Lei Zhao
YYYasuto Yamaguchi
Yasuto Yamaguchi
XGXiaomei Ge
Xiaomei Ge
WRWilliam H. Robinson
William H. Robinson
JMJohn Morser
John Morser
LLLawrence L. K. Leung
Lawrence L. K. Leung
Chemerin is a chemoattractant involved in immunity that also functions as an adipokine. Chemerin is secreted as an inactive precursor (chem163S), and its activation requires proteolytic cleavages at its C-terminus, involving proteases in coagulation, fibrinolysis, and inflammation. Previously, we found chem158K was the dominant chemerin form in synovial fluids from patients with arthritis. In this study, we aimed to characterize a distinct cleaved chemerin form, chem156F, in osteoarthritis (OA) and rheumatoid arthritis (RA). Purified chem156F was produced in transfected CHO cells. To quantify chem156F in OA and RA samples, we developed a specific ELISA for chem156F using antibody raised against a peptide representing the C-terminus of chem156F. Ca2+ mobilization assays showed that the EC50 values for chem163S, chem156F, and chem157S were 252 ± 141 nM, 133 ± 41.5 nM, and 5.83 ± 2.48 nM, respectively. chem156F was more active than its precursor, chem163S, but very much less potent than chem157S, the most active chemerin form. Chymase was shown to be capable of cleaving chem163S at a relevant rate. Using the chem156F ELISA we found a substantial amount of chem156F present in synovial fluids from patients with OA and RA, 24.06 ± 5.51 ng/ml and 20.35 ± 5.19 ng/ml (mean ± SEM, n = 25) respectively, representing 20% of total chemerin in OA and 76.7% of chemerin in RA synovial fluids. Our data show that chymase cleavage of chem163S to partially active chem156F can be found in synovial fluids where it can play a role in modulation of the inflammation in joints.

16 February 2022 in Journal of Thrombosis and Haemostasis
Verified
Journal Article
Closed access
SPSameera Peraramelli
Sameera Peraramelli
QZQi Zhou
Qi Zhou
QZQin Zhou
Qin Zhou
BWBettina Wanko
Bettina Wanko
LZLei Zhao
Lei Zhao
LLLawrence L.K. Leung
Lawrence L.K. Leung

22 April 2024 in Biomedicines
Verified
Journal Article
Open access
PDF file
LZLei Zhao
Lei Zhao
JZJonathan Hongde Zhou
Jonathan Hongde Zhou
FAFahim Abbasi
Fahim Abbasi
MFMohsen Fathzadeh
Mohsen Fathzadeh
JKJosh Knowles
Josh Knowles
JMJohn Morser
John Morser
Chemerin is a chemokine/adipokine, regulating inflammation, adipogenesis and energy metabolism whose activity depends on successive proteolytic cleavages at its C-terminus. Chemerin levels and processing are correlated with insulin resistance. We hypothesized that chemerin processing would be higher in individuals with type 2 diabetes (T2D) and in those who are insulin resistant (IR). This hypothesis was tested by characterizing different chemerin forms by specific ELISA in the plasma of 18 participants with T2D and 116 without T2D who also had their insulin resistance measured by steady-state plasma glucose (SSPG) concentration during an insulin suppression test. This approach enabled us to analyze the association of chemerin levels with a direct measure of insulin resistance (SSPG concentration). Participants were divided into groups based on their degree of insulin resistance using SSPG concentration tertiles: insulin sensitive (IS, SSPG ≤ 91 mg/dL), intermediate IR (IM, SSPG 92–199 mg/dL), and IR (SSPG ≥ 200 mg/dL). Levels of different chemerin forms were highest in patients with T2D, second highest in individuals without T2D who were IR, and lowest in persons without T2D who were IM or IS. In the whole group, chemerin levels positively correlated with both degree of insulin resistance (SSPG concentration) and adiposity (BMI). Participants with T2D and those without T2D who were IR had the most proteolytic processing of chemerin, resulting in higher levels of both cleaved and degraded chemerin. This suggests that increased inflammation in individuals who have T2D or are IR causes more chemerin processing.

30 April 2024 in Biomedicines
Verified
Journal Article
Open access
PDF file
AMAishee Bhattacharya Mukherji
Aishee Bhattacharya Mukherji
VIVictoria Idowu
Victoria Idowu
LZLei Zhao
Lei Zhao
LLLawrence L. K. Leung
Lawrence L. K. Leung
SSSa Shen
Sa Shen
JMJohn Morser
John Morser
Chemerin acts as both a chemotactic agent and an adipokine that undergoes proteolytic cleavage, converting inactive precursors into their active forms before being subsequently inactivated. Elevated chemerin levels are linked to obesity and type 2 diabetes mellitus (T2D). This study aimed to elucidate the effects of T2D and obesity on chemerin levels by comparing plasma samples from individuals with a normal weight and T2D (BMI < 25; NWD group n = 22) with those from individuals who are overweight or obese and have T2D (BMI ≥ 25; OWD group n = 39). The total chemerin levels were similar in the NWD and OWD groups, suggesting that T2D may equalize the chemerin levels irrespective of obesity status. The cleavage of chemerin has been previously linked to myocardial infarction and stroke in NWD, with potential implications for inflammation and mortality. OWD plasma exhibited lower levels of cleaved chemerin than the NWD group, suggesting less inflammation in the OWD group. Here, we showed that the interaction between obesity and T2D leads to an equalization in the total chemerin levels. The cleaved chemerin levels and the associated inflammatory state, however, differ significantly, underscoring the complex relationship between chemerin, T2D, and obesity.